Highlights Lumos Pharma, Inc.

Equities

LUMO

US55028X1090

Market Closed - Nasdaq Other stock markets 04:00:00 2024-07-12 pm EDT			5-day change	1st Jan Change
1.65 ^USD	-6.78%		-25.34%	-48.11%

Jun. 04	Lumos Pharma, Inc. Announces New Analyses of Phase 2 OraGrowtH212 Trial Presented at ENDO 2024	CI
May. 15	Lumos Pharma Announces Positive End-of-Phase 2 Meeting with FDA	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Lumos Pharma, Inc. Announces New Analyses of Phase 2 OraGrowtH212 Trial Presented at ENDO 2024	Jun. 04	CI
Lumos Pharma Announces Positive End-of-Phase 2 Meeting with FDA	May. 15	CI
Lumos Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 15	CI
Lumos Pharma Plans Phase 3 Study of Growth Hormone Drug	May. 14	MT
Earnings Flash (LUMO) LUMOS PHARMA Posts Q1 Revenue $165,000, vs. Street Est of $0.3M	May. 14	MT
Lumos Pharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 07	CI
Earnings Flash (LUMO) LUMOS PHARMA Reports Q4 Revenue $2.1M	Mar. 07	MT
Lumos Pharma Phase 2 Trials Targeting Pediatric Growth Hormone Deficiency Meet Endpoints; Shares Surge Premarket	Nov. 08	MT
Tranche Update on Lumos Pharma, Inc.'s Equity Buyback Plan announced on August 16, 2022.	Nov. 07	CI
Lumos Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 07	CI
Earnings Flash (LUMO) LUMOS PHARMA Posts Q3 Revenue $7,000	Nov. 07	MT
Lumos Pharma, Inc. Announces Topline Data from Phase 2 OraGrowtH210 and OraGrowtH212 Trials of LUM-201 inPGHD Met All Primary and Secondary Endpoints	Nov. 07	CI
Lumos Pharma Announces New Data and Analysis of 15 Subjects from Oragrowth212 Trial Presented At the 2023 ESPE Annual Meeting	23-09-26	CI
Lumos Pharma, Inc. Announces Abstract Accepted for Oral Presentation at the European Society for Paediatric Endocrinology Annual Meeting	23-09-14	CI
Lumos Pharma, Inc.'s Equity Buyback announced on August 16, 2022, has expired with 517,468 shares, representing 6.30% for $1.96 million.	23-08-16	CI
Tranche Update on Lumos Pharma, Inc.'s Equity Buyback Plan announced on August 16, 2022.	23-08-10	CI
Lumos Pharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-09	CI
Earnings Flash (LUMO) LUMOS PHARMA Posts Q2 Revenue $527,000, vs. Street Est of $0.2M	23-08-09	MT
Lumos to Highlight New LUM-201 Data and Analysis Presented at ENDO 2023 in Virtual KOL Webinar	23-06-21	CI
Lumos Pharma, Inc. Announces Encouraging Data from Lumos Pharma OraGrowtH Trials Presented at Annual Pediatric Endocrine Society Meeting	23-05-08	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Lumos Pharma, Inc.

Equities

LUMO

US55028X1090

Highlights

Filters